![Exo Therapeutics logo](/sites/dolphinusspare3_novartis_com/files/styles/twoup_layout_desktop_1080/public/2023-12/EXO.jpg?itok=BrE4FryJ)
Exo Therapeutics
Aaron Nelson - Director
Michelle Ma - Observer
Oncology, Platform
Boston, USA
Exo Therapeutics is developing small-molecule enzyme inhibitors that target distal binding pockets to reprogram enzyme activity with a focus on high-value oncology indications.